Goldman Sachs Maintains Buy on Ascendis Pharma, Raises Price Target to $200
Portfolio Pulse from Benzinga Newsdesk
Goldman Sachs analyst Paul Choi has maintained a Buy rating on Ascendis Pharma and increased the price target from $180 to $200.
September 17, 2024 | 1:26 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Goldman Sachs has reaffirmed its Buy rating on Ascendis Pharma and increased the price target to $200, indicating confidence in the company's future performance.
The increase in price target from $180 to $200 by a reputable firm like Goldman Sachs suggests a positive outlook for Ascendis Pharma. This is likely to boost investor confidence and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100